The biopharma firm reported Q2 revenue of $215.3M, falling short of expectations by $5.54M.
Harmony Biosciences Holdings, Inc. reported a GAAP EPS of $0.55 for the quarter, missing analyst estimates by $0.14. Revenue reached $215.3M, $5.54M below consensus forecasts.
Analysts had anticipated stronger earnings and revenue growth, following a prior quarter where the company outperformed expectations. The miss contrasts with recent trends in the biopharma sector, where several firms have exceeded projections.
Shares may face pressure as investors reassess growth expectations amid the earnings shortfall.